A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...

In the early stages, fatty liver may be asymptomatic, with most people unaware they have it. However, continued fat buildup ...

For the first time, the European Medicines Agency has recognized AI software for the diagnosis of fatty liver hepatitis as ...

tool called AIM-NASH in clinical trials to help identify the severity of a type of fatty liver disease. The condition, called metabolic dysfunction-associated steatohepatitis, or MASH, is a ...

The doctor explained that beside alcohol consumption and hepatitis, hypertension can contribute significantly to liver fibrosis.

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a ...

The European Medicines Agency (EMA) gave its approval to an artificial intelligence diagnostic tool for the first time on ...